MCID: DBT006
MIFTS: 48

Diabetic Macular Edema

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Diabetic Macular Edema

MalaCards integrated aliases for Diabetic Macular Edema:

Name: Diabetic Macular Edema 12 54 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9191
ICD9CM 34 362.07
SNOMED-CT 67 312912001
UMLS 70 C0730285

Summaries for Diabetic Macular Edema

MalaCards based summary : Diabetic Macular Edema is related to macular retinal edema and endophthalmitis. An important gene associated with Diabetic Macular Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Diclofenac and Bromfenac have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and retina, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Diabetic Macular Edema

Diseases related to Diabetic Macular Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 295)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 32.3 VEGFA SERPINF1 PRKCB IL6 ICAM1 CCL2
2 endophthalmitis 31.7 VEGFA IL6 ICAM1
3 background diabetic retinopathy 31.5 VEGFA IL6 ICAM1 AKR1B1
4 microvascular complications of diabetes 5 31.3 VEGFA TEK SERPINF1 PRKCB NOS3 ICAM1
5 macular holes 31.2 VEGFA SERPINF1 IL6 CCL2
6 retinal vein occlusion 31.2 VEGFA SERPINF1 IL6 CCL2
7 retinal microaneurysm 31.2 VEGFA REN AKR1B1
8 central retinal vein occlusion 31.0 VEGFA SERPINF1 IL6
9 kuhnt-junius degeneration 31.0 VEGFC VEGFA TEK SERPINF1
10 retinal detachment 30.9 VEGFA SERPINF1 IL6 GFAP FGF2 EPO
11 cataract 30.9 VEGFA SERPINF1 IL6 ICAM1 HIF1A FGF2
12 uveitis 30.9 SERPINF1 IL6 ICAM1 CCL2
13 severe nonproliferative diabetic retinopathy 30.7 VEGFA REN PRKCB ICAM1 CCL2 AKR1B1
14 retinal artery occlusion 30.6 VEGFA IL6 CCL2
15 leukostasis 30.6 VEGFA SERPINF1 ICAM1 CCL2
16 iritis 30.5 VEGFA IL6 EPO
17 hyperglycemia 30.5 SST PRKCB NOS3 IL6 HIF1A AKR1B1
18 angina pectoris 30.4 NOS3 IL6 ICAM1
19 conjunctivitis 30.4 IL6 ICAM1 CCL2
20 peripheral vascular disease 30.3 VEGFA IL6 EPO CCL2
21 retinal vascular occlusion 30.2 VEGFA SERPINF1 IL6 ICAM1 CCL2
22 brain edema 30.1 VEGFA IL6 GFAP
23 congestive heart failure 30.0 VEGFA REN NOS3 IL6 EPO
24 vascular disease 30.0 VEGFA REN NOS3 IL6 ICAM1 FGF2
25 eye disease 30.0 VEGFA SST SERPINF1 PRKCB IL6 ICAM1
26 macular degeneration, age-related, 1 30.0 VEGFC VEGFA TEK SERPINF1 IL6 ICAM1
27 microvascular complications of diabetes 1 30.0 VEGFA SST SERPINF1 IL6 ICAM1 HIF1A
28 end stage renal disease 29.9 VEGFA REN NOS3 IL6 ICAM1 EPO
29 type 1 diabetes mellitus 29.9 VEGFA SST REN IL6 ICAM1 CCL2
30 chronic kidney disease 29.9 VEGFA REN NOS3 IL6 ICAM1 EPO
31 sleep apnea 29.9 VEGFA REN NOS3 IL6 ICAM1 HIF1A
32 diabetic neuropathy 29.8 VEGFA REN PRKCB ICAM1 FGF2 EPO
33 retinal vascular disease 29.8 VEGFA TEK SERPINF1 REN NOS3 IL6
34 ischemia 29.8 VEGFA TEK NOS3 ICAM1 HIF1A GFAP
35 nervous system disease 29.8 VEGFA IL6 GFAP FGF2 CCL2
36 apnea, obstructive sleep 29.8 VEGFA REN NOS3 IL6 ICAM1 HIF1A
37 retinal degeneration 29.6 SERPINF1 KCNJ10 FGF2 EPO AKR1B1
38 diabetes mellitus 29.0 VEGFA SST REN PRKCB NOS3 IL6
39 type 2 diabetes mellitus 28.9 VEGFA SST REN PRKCB NOS3 IL6
40 hypertension, essential 28.1 VEGFC VEGFA TEK SST REN NOS3
41 microvascular complications of diabetes 2 11.0
42 yemenite deaf-blind hypopigmentation syndrome 10.9
43 vitreous detachment 10.8
44 retinal disease 10.7
45 ocular hypertension 10.7
46 cytokine deficiency 10.6
47 lipid metabolism disorder 10.5
48 vibrio vulnificus infection 10.4 IL6 EPO
49 retinal ischemia 10.4
50 hemifacial spasm 10.4 VEGFA NOS3

Graphical network of the top 20 diseases related to Diabetic Macular Edema:



Diseases related to Diabetic Macular Edema

Symptoms & Phenotypes for Diabetic Macular Edema

MGI Mouse Phenotypes related to Diabetic Macular Edema:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 AKR1B1 ANGPTL4 CASP14 EPO FGF2 GFAP
2 cardiovascular system MP:0005385 10.34 ANGPTL4 EPO FGF2 GFAP HIF1A ICAM1
3 hematopoietic system MP:0005397 10.33 ANGPTL4 CASP14 EPO FGF2 HIF1A HPX
4 immune system MP:0005387 10.33 ANGPTL4 CASP14 CCL2 EPO GFAP HIF1A
5 mortality/aging MP:0010768 10.27 AKR1B1 ANGPTL4 EPO FGF2 GFAP HIF1A
6 digestive/alimentary MP:0005381 10.13 ANGPTL4 GFAP HIF1A ICAM1 IL6 NOS3
7 nervous system MP:0003631 10.1 ANGPTL4 FGF2 GFAP HIF1A ICAM1 IL6
8 muscle MP:0005369 10.02 EPO FGF2 GFAP HIF1A ICAM1 IL6
9 renal/urinary system MP:0005367 9.76 AKR1B1 HIF1A HPX IL6 KCNJ10 NOS3
10 skeleton MP:0005390 9.65 AKR1B1 ANGPTL4 EPO FGF2 HIF1A IL6
11 vision/eye MP:0005391 9.4 AKR1B1 ANGPTL4 FGF2 GFAP HIF1A ICAM1

Drugs & Therapeutics for Diabetic Macular Edema

Drugs for Diabetic Macular Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Bromfenac Approved Phase 4 91714-94-2 60726
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
9
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
10
Homatropine Approved Phase 4 87-00-3
11
Bevacizumab Approved, Investigational Phase 4 216974-75-3
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
14
Lactitol Approved, Investigational Phase 4 585-86-4 157355
15
Glimepiride Approved Phase 4 93479-97-1 3476
16
Empagliflozin Approved Phase 4 864070-44-0
17 Analgesics, Non-Narcotic Phase 4
18 Antirheumatic Agents Phase 4
19 Analgesics Phase 4
20 Pharmaceutical Solutions Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22 Antineoplastic Agents, Immunological Phase 4
23 Antibiotics, Antitubercular Phase 4
24 Anti-Bacterial Agents Phase 4
25 Norgestimate, ethinyl estradiol drug combination Phase 4
26 Anesthetics Phase 4
27 Mitogens Phase 4
28 Endothelial Growth Factors Phase 4
29
protease inhibitors Phase 4
30 HIV Protease Inhibitors Phase 4
31 Gastrointestinal Agents Phase 4
32 Antiemetics Phase 4
33 Antineoplastic Agents, Hormonal Phase 4
34 BB 1101 Phase 4
35 Immunosuppressive Agents Phase 4
36 Immunologic Factors Phase 4
37 insulin Phase 4
38 Insulin, Globin Zinc Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Sodium-Glucose Transporter 2 Inhibitors Phase 4
41 Hypoglycemic Agents Phase 4
42
Temazepam Approved, Investigational Phase 3 846-50-4 5391
43
Ketorolac Approved Phase 2, Phase 3 74103-06-3, 66635-83-4 3826
44
Danazol Approved Phase 3 17230-88-5 28417
45
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
46
Povidone Approved Phase 3 9003-39-8 131751496
47
Iodine Approved, Investigational Phase 3 7553-56-2 807
48
Infliximab Approved Phase 3 170277-31-3
49
Ruboxistaurin Investigational Phase 3 202260-21-7, 169939-94-0 153999
50
Fasudil Investigational Phase 3 103745-39-7

Interventional clinical trials:

(show top 50) (show all 437)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Center, Randomized, Double Blind, Double Arm, Comparative Clinical Trial to Compare the Safety and Preliminary Efficacy Between Ranibizumab Monotherapy and Ranibizumab Combined With R:GEN (Selective Retina Therapy) in Clinically Significant Diabetic Macular Edema (a Pilot Study) Unknown status NCT03759860 Phase 4
2 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
3 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
4 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
5 The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor Unknown status NCT03475407 Phase 4 Ozurdex intravitreal injection
6 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
7 Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Clinical Trial Unknown status NCT03197480 Phase 4 Aflibercept Injection [Eylea]
8 A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg Unknown status NCT02424019 Phase 4 ILUVIEN 0.19 MG
9 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
10 Single Arm, Single Dose Clinical Study to Investigate Efficacy of Treat-and-Extend Regimen of Intravitreal Aflibercept Injection in Diabetic Macular Edema Unknown status NCT02788877 Phase 4 aflibercept
11 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
12 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
13 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
14 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
15 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
16 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
17 A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
18 Ranibizumab and Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema Completed NCT04089605 Phase 4 dexamethasone implant;Ranibizumab
19 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
20 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
21 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
22 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
23 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial . Completed NCT02299336 Phase 4 Aflibercept
24 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Completed NCT03097068 Phase 4 Lucentis
25 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
26 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 1 Trial) Completed NCT02297204 Phase 4 aflibercept 2.0 mg
27 Aflibercept With Adjuvant Micro-Pulsed Yellow Laser Versus Aflibercept Monotherapy in Treatment of Diabetic Macular Edema. Completed NCT03866746 Phase 4 Aflibercept Injection
28 Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial Completed NCT02734407 Phase 4 aflibercept 2.0 mg
29 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
30 Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab Completed NCT03340610 Phase 4 Alflibercept
31 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
32 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
33 A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema Completed NCT02633852 Phase 4 Aflibercept
34 A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
35 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
36 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Treatment Naïve Patients With Diabetic Macular Edema Completed NCT02441907 Phase 4 aflibercept
37 Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
38 A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study) Completed NCT04619303 Phase 4 Dexamethasone intravitreal implant;Bevacizumab Injectable Product
39 Central Macular Thickness, Macular Electroretinogram, and Visual Acuity in Patients With Diabetic Macular Edema After Intravitreal Aflibercept Injection. A One Month Pre-Post Intervention Follow Up Study Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
40 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
41 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
42 Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema Completed NCT04087746 Phase 4 Aflibercept;Ranibizumab
43 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
44 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
45 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
46 Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab Completed NCT02559180 Phase 4 aflibercept
47 Yellow Micropulse Laser 577-nm vs Infrared Diode Micropulse Laser 810-nm for the Treatment of Diabetic Macular Edema Completed NCT04359771 Phase 4
48 Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
49 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
50 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study Recruiting NCT03056079 Phase 4 Intravitreal aflibercept

Search NIH Clinical Center for Diabetic Macular Edema

Genetic Tests for Diabetic Macular Edema

Anatomical Context for Diabetic Macular Edema

MalaCards organs/tissues related to Diabetic Macular Edema:

40
Endothelial, Eye, Retina, Brain, Cortex, Pancreas, Neutrophil

Publications for Diabetic Macular Edema

Articles related to Diabetic Macular Edema:

(show top 50) (show all 3634)
# Title Authors PMID Year
1
Update on treatments of diabetic macular edema. 54 61
19951615 2009
2
Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. 61 54
19060271 2009
3
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. 54 61
19381089 2009
4
Treating diabetic retinopathy by inhibiting growth factor pathways. 61 54
19337953 2009
5
Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. 54 61
18328456 2008
6
Spontaneous resolution of vitreomacular traction following ranibizumab (Lucentis) injection. 61 54
18320528 2008
7
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. 54 61
17245083 2007
8
Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. 61 54
17505145 2007
9
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. 54 61
17046701 2006
10
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. 54 61
16406543 2006
11
Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. 54 61
16186374 2005
12
Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. 61 54
15963467 2005
13
Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. 54 61
15878060 2005
14
Pharmacotherapy for diabetic retinopathy. 61 54
15523197 2004
15
Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. 54 61
15096582 2004
16
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. 61 54
13129863 2003
17
VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. 54 61
12652651 2003
18
Relation of diabetic macular edema to cytokines and posterior vitreous detachment. 61 54
12614749 2003
19
[The influence of spontaneous posterior vitreous detachment in resolution of diabetic macular edema in NIDDM]. 61 54
15049255 2003
20
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. 61 54
11931788 2002
21
Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. 54 61
11755841 2002
22
Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. 54 61
11530050 2001
23
New surgical approach for removing massive foveal hard exudates in diabetic macular edema. 54 61
9951473 1999
24
Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study. 61
33130144 2021
25
Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study. 61
33789617 2021
26
Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. 61
32941962 2021
27
Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. 61
32997288 2021
28
Differences in the characteristics of subjects achieving complete, partial, or no resolution of macular edema in the READ-3 study. 61
33792788 2021
29
Correlation of Response between Both Eyes to First- and Second-Line Anti-VEGF Therapy in Diabetic Macular Edema. 61
32804540 2021
30
Quantitative evaluation of hard exudates in diabetic macular edema by multicolor imaging and their associations with serum lipid levels. 61
33811294 2021
31
Prospective Study of Silicone Oil Microdroplets in Eyes Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in 3 Different Syringes. 61
32735904 2021
32
OctNET: A Lightweight CNN for Retinal Disease Classification from Optical Coherence Tomography Images. 61
33339630 2021
33
The Relationship between Choroidal Thickness and Intracellular Oxidised-reduced Glutathione and Extracellular Thiol-disulfide Homeostasis at Different Stages of Diabetic Retinopathy. 61
33103488 2021
34
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. 61
33784735 2021
35
Evaluation of morphological characteristics of diabetic macular edema in patients with non-proliferative versus proliferative diabetic retinopathy: a spectral-domain optical coherence tomography study. 61
33772414 2021
36
Wide Field Swept Source Optical Coherence Tomography Angiography for the Evaluation of Proliferative Diabetic Retinopathy and Associated Lesions: A Review. 61
33734945 2021
37
Effectiveness and Safety of Coadministration of Intravitreal Dexamethasone Implant and Silicone Oil Endotamponade for Proliferative Diabetic Retinopathy with Tractional Diabetic Macular Edema. 61
33325793 2021
38
Dexamethasone implant migration in an eye with congenital glaucoma: A case report and review of the literature. 61
33781105 2021
39
Characteristics and surgical outcomes of rhegmatogenous retinal detachments that develop after intravitreal injections. 61
33745092 2021
40
Natural History and Predictors of Vision Loss in Eyes with Diabetic Macular Edema and Good Initial Visual Acuity. 61
33734192 2021
41
Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown. 61
33595512 2021
42
A dynamic nomogram for predicting diabetic macular edema in type 2 diabetes patients based on plasma cytokines. 61
33686950 2021
43
Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation. 61
33783677 2021
44
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. 61
33471572 2021
45
Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database. 61
33420855 2021
46
Combination Approaches Targeting Neurodegeneration, Oxidative stress and Inflammation in the Treatment of Diabetic Retinopathy. 61
33745432 2021
47
Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration. 61
33775825 2021
48
Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema. 61
33810434 2021
49
Astaxanthin mediated regulation of VEGF through HIF1α and XBP1 signaling pathway: An insight from ARPE-19 cell and streptozotocin mediated diabetic rat model. 61
33789142 2021
50
Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti-VEGF Therapy for Diabetic Macular Edema in the United States. 61
33716048 2021

Variations for Diabetic Macular Edema

Expression for Diabetic Macular Edema

Search GEO for disease gene expression data for Diabetic Macular Edema.

Pathways for Diabetic Macular Edema

Pathways related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 VEGFC VEGFA TEK IL6 ICAM1 FGF2
2
Show member pathways
13.34 VEGFA TEK IL6 ICAM1 HIF1A FGF2
3
Show member pathways
13.26 VEGFC VEGFA TEK PRKCB NOS3 IL6
4
Show member pathways
12.98 VEGFC REN PRKCB IL6 HIF1A FGF2
5
Show member pathways
12.9 VEGFC VEGFA TEK NOS3 IL6 FGF2
6
Show member pathways
12.85 VEGFA PRKCB IL6 ICAM1 HIF1A FGF2
7 12.76 VEGFC VEGFA PRKCB IL6 HIF1A FGF2
8 12.75 VEGFC VEGFA TEK PRKCB FGF2
9
Show member pathways
12.72 VEGFC VEGFA TEK PRKCB FGF2
10
Show member pathways
12.65 VEGFC VEGFA SST PRKCB NOS3
11
Show member pathways
12.63 VEGFA PRKCB NOS3 ICAM1 CCL2
12
Show member pathways
12.58 VEGFA PRKCB IL6 HIF1A FGF2
13
Show member pathways
12.55 TEK NOS3 IL6 FGF2 CCL2
14
Show member pathways
12.42 VEGFC VEGFA PRKCB NOS3 FGF2 CASP14
15
Show member pathways
12.35 VEGFA PRKCB NOS3 ICAM1 CCL2
16 12.33 VEGFC VEGFA PRKCB NOS3 FGF2
17 12.29 VEGFA PRKCB HIF1A FGF2
18
Show member pathways
12.28 VEGFA PRKCB HIF1A CCL2
19 12.14 VEGFA SST IL6 HIF1A
20 12.06 VEGFA NOS3 ICAM1 CCL2
21 11.96 IL6 ICAM1 GFAP CCL2
22 11.93 VEGFC IL6 ICAM1 CCL2
23 11.86 VEGFA IL6 ICAM1 HIF1A FGF2 CCL2
24
Show member pathways
11.8 VEGFC VEGFA NOS3 HIF1A
25 11.77 VEGFA GFAP FGF2
26 11.77 VEGFA TEK IL6 ICAM1 CCL2
27 11.74 VEGFA TEK PRKCB NOS3 IL6 HIF1A
28 11.68 PRKCB NOS3 HIF1A
29 11.67 VEGFA HIF1A EPO
30
Show member pathways
11.64 VEGFA IL6 ICAM1
31 11.64 IL6 FGF2 CCL2
32 11.53 VEGFA IL6 HIF1A
33 11.52 IL6 ICAM1 CCL2
34 11.5 IL6 ICAM1 CCL2
35 11.5 VEGFC VEGFA NOS3 HIF1A EPO
36 11.5 VEGFC VEGFA PRKCB NOS3 IL6 ICAM1
37 11.44 VEGFA IL6 FGF2 EPO
38 11.36 VEGFA HIF1A EPO
39 11.35 PRKCB IL6 ICAM1
40 11.3 NOS3 IL6 CCL2
41 11.12 VEGFC TEK REN NOS3 HIF1A FGF2
42 11.03 VEGFA TEK NOS3 HIF1A FGF2
43 10.98 VEGFC TEK IL6 GFAP FGF2 CCL2
44 10.56 VEGFC VEGFA HIF1A

GO Terms for Diabetic Macular Edema

Cellular components related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 VEGFC VEGFA TEK SST SERPINF1 REN
2 extracellular space GO:0005615 9.44 VEGFC VEGFA SST SERPINF1 REN IL6
3 cell body GO:0044297 9.33 KCNJ10 GFAP EPO

Biological processes related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 VEGFC VEGFA TEK PRKCB IL6 HIF1A
2 positive regulation of gene expression GO:0010628 10.04 VEGFA NOS3 IL6 HIF1A FGF2
3 negative regulation of apoptotic process GO:0043066 9.98 VEGFA TEK IL6 HIF1A EPO ANGPTL4
4 positive regulation of protein phosphorylation GO:0001934 9.92 VEGFC VEGFA TEK FGF2
5 response to lipopolysaccharide GO:0032496 9.88 REN NOS3 ICAM1 EPO
6 cytokine-mediated signaling pathway GO:0019221 9.88 VEGFA IL6 ICAM1 HIF1A FGF2 CCL2
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 VEGFA TEK ICAM1 FGF2 EPO CCL2
8 response to organic substance GO:0010033 9.82 TEK REN AKR1B1
9 cellular response to interleukin-1 GO:0071347 9.82 ICAM1 HIF1A CCL2
10 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.81 VEGFA HIF1A EPO
11 positive regulation of MAPK cascade GO:0043410 9.81 VEGFA TEK IL6 FGF2
12 positive regulation of endothelial cell migration GO:0010595 9.8 VEGFA TEK FGF2
13 angiogenesis GO:0001525 9.8 VEGFC VEGFA TEK HIF1A FGF2 CCL2
14 positive regulation of epithelial cell proliferation GO:0050679 9.79 VEGFC VEGFA FGF2
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 VEGFA TEK FGF2 EPO
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 VEGFA IL6 HPX EPO
17 positive regulation of cell division GO:0051781 9.74 VEGFC VEGFA FGF2
18 positive chemotaxis GO:0050918 9.73 VEGFC VEGFA FGF2
19 positive regulation of endothelial cell proliferation GO:0001938 9.72 VEGFC VEGFA TEK HIF1A FGF2
20 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 TEK ICAM1 ANGPTL4
21 sprouting angiogenesis GO:0002040 9.7 VEGFC VEGFA TEK
22 positive regulation of neuroblast proliferation GO:0002052 9.67 VEGFC VEGFA HIF1A
23 vascular endothelial growth factor production GO:0010573 9.61 IL6 HIF1A
24 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.61 VEGFA HIF1A
25 positive regulation of mast cell chemotaxis GO:0060754 9.6 VEGFC VEGFA
26 hemoglobin biosynthetic process GO:0042541 9.59 HIF1A EPO
27 positive regulation of epithelial tube formation GO:1905278 9.55 VEGFA FGF2
28 positive regulation of blood vessel endothelial cell migration GO:0043536 9.55 VEGFC VEGFA NOS3 HIF1A FGF2
29 response to hypoxia GO:0001666 9.5 VEGFC VEGFA TEK ICAM1 HIF1A EPO
30 positive regulation of angiogenesis GO:0045766 9.23 VEGFC VEGFA TEK PRKCB NOS3 HIF1A

Molecular functions related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 VEGFC VEGFA TEK SST SERPINF1 REN
2 growth factor activity GO:0008083 9.56 VEGFC VEGFA IL6 FGF2
3 chemoattractant activity GO:0042056 9.33 VEGFC VEGFA FGF2
4 vascular endothelial growth factor receptor binding GO:0005172 9.32 VEGFC VEGFA
5 cytokine activity GO:0005125 9.02 VEGFA IL6 FGF2 EPO CCL2

Sources for Diabetic Macular Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....